跳至主要内容
临床试验/NL-OMON52739
NL-OMON52739招募中不适用

The search for biomarkers to enable detection and monitoring of disease progression from NAFLD to NASH and NASH itself; Amsterdam NASH cohort - Amsterdam NASH cohort (ANCHOR) study

Academisch Medisch Centrum0 个研究点目标入组 300 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Diagnosis of steatosis hepatis on ultrasound or by biopsy or on Fibroscan
  • with CAP >280dB/m
  • >18 years of age
  • ASAT and/or ALAT levels above upper limit of normal in six months prior to
  • BMI >25 kg/m2

排除标准

  • Abusive alcohol use (>20 IU/week)
  • Hepatitis B and/or C
  • Auto-immune hepatitis
  • Wilsons disease/ alpha-1-antitripsine deficiency
  • Haemachromatose
  • Bleeding disorder, including the use of anticoagulant therapy and platelet
  • aggregation inhibitors. Except for subjects using platelet aggregation
  • inhibition monotherapy for the prevention of cardiovascular disease and without
  • a history of any coronary events. In this case the platelet aggregation
  • inhibitor will be discontinued for 7 days before the liver biopsy is performed.
  • Use of drugs with a potential role in aggravation of pre-existing NAFLD
  • Not able or willing to undergo MRI (for example claustrophobia, ICD,
  • pacemaker).
  • Diagnosis of liver cirrhosis and/or hepatocellular carcinoma.

研究者

相似试验